Share-based Payment Arrangement, Expense of MADRIGAL PHARMACEUTICALS, INC. from 31 Dec 2010 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
MADRIGAL PHARMACEUTICALS, INC. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2010 to 30 Sep 2025.
  • MADRIGAL PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $26,252,000, a 47% increase year-over-year.
  • MADRIGAL PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $90,018,000, a 17% increase year-over-year.
  • MADRIGAL PHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2024 was $79,880,000, a 61% increase from 2023.
  • MADRIGAL PHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2023 was $49,735,000, a 57% increase from 2022.
  • MADRIGAL PHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2022 was $31,625,000, a 18% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

MADRIGAL PHARMACEUTICALS, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $90,018,000 $26,252,000 +$8,354,000 +47% 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $81,664,000 $25,159,000 +$755,000 +3.1% 01 Apr 2025 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $80,909,000 $20,931,000 +$1,029,000 +5.2% 01 Jan 2025 31 Mar 2025 10-Q 01 May 2025 2025 Q1
Q4 2024 $79,880,000 $17,676,000 +$2,824,000 +19% 01 Oct 2024 31 Dec 2024 10-K 26 Feb 2025 2024 FY
Q3 2024 $77,056,000 $17,898,000 +$5,238,000 +41% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025 2025 Q3
Q2 2024 $71,818,000 $24,404,000 +$13,431,000 +122% 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2025 2025 Q2
Q1 2024 $58,387,000 $19,902,000 +$8,652,000 +77% 01 Jan 2024 31 Mar 2024 10-Q 01 May 2025 2025 Q1
Q4 2023 $49,735,000 $14,852,000 +$6,770,000 +84% 01 Oct 2023 31 Dec 2023 10-K 26 Feb 2025 2024 FY
Q3 2023 $42,965,000 $12,660,000 +$4,538,000 +56% 01 Jul 2023 30 Sep 2023 10-Q 31 Oct 2024 2024 Q3
Q2 2023 $38,427,000 $10,973,000 +$3,029,000 +38% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024 2024 Q2
Q1 2023 $35,398,000 $11,250,000 +$3,773,000 +50% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $31,625,000 $8,082,000 +$1,725,000 +27% 01 Oct 2022 31 Dec 2022 10-K 26 Feb 2025 2024 FY
Q3 2022 $29,900,000 $8,122,000 +$1,881,000 +30% 01 Jul 2022 30 Sep 2022 10-Q 06 Nov 2023 2023 Q3
Q2 2022 $28,019,000 $7,944,000 -$235,000 -2.9% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $28,254,000 $7,477,000 +$1,381,000 +23% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $26,873,000 $6,357,000 +$1,223,000 +24% 01 Oct 2021 31 Dec 2021 10-K 28 Feb 2024 2023 FY
Q3 2021 $25,650,000 $6,241,000 +$1,180,000 +23% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $24,470,000 $8,179,000 +$2,490,000 +44% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $21,980,000 $6,096,000 +$1,250,000 +26% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q4 2020 $20,730,000 $5,134,000 +$1,102,000 +27% 01 Oct 2020 31 Dec 2020 10-K/A 03 Mar 2023 2022 FY
Q3 2020 $19,628,000 $5,061,000 +$111,000 +2.2% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $19,517,000 $5,689,000 -$2,066,000 -27% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $21,583,000 $4,846,000 -$1,176,000 -20% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $22,759,000 $4,032,000 -$1,087,000 -21% 01 Oct 2019 31 Dec 2019 10-K 24 Feb 2022 2021 FY
Q3 2019 $23,846,000 $4,950,000 -$26,000 -0.52% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $23,872,000 $7,755,000 +$5,528,000 +248% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 $18,344,000 $6,022,000 +$4,855,000 +416% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $13,489,000 $5,119,000 +$4,172,000 +441% 01 Oct 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
Q3 2018 $9,317,000 $4,976,000 +$3,947,000 +384% 01 Jul 2018 30 Sep 2018 10-Q 06 Nov 2019 2019 Q3
Q2 2018 $5,370,000 $2,227,000 +$1,551,000 +229% 01 Apr 2018 30 Jun 2018 10-Q 07 Aug 2019 2019 Q2
Q1 2018 $3,819,000 $1,167,000 +$565,000 +94% 01 Jan 2018 31 Mar 2018 10-Q 08 May 2019 2019 Q1
Q4 2017 $3,254,000 $947,000 +$1,364,000 01 Oct 2017 31 Dec 2017 10-K 26 Feb 2020 2019 FY
Q3 2017 $1,890,000 $1,029,000 -$6,324,000 -86% 01 Jul 2017 30 Sep 2017 10-Q 06 Nov 2018 2018 Q3
Q2 2017 $8,214,000 $676,000 +$131,000 +24% 01 Apr 2017 30 Jun 2017 10-Q 07 Aug 2018 2018 Q2
Q1 2017 $8,083,000 $602,000 +$154,000 +34% 01 Jan 2017 31 Mar 2017 10-Q 08 May 2018 2018 Q1
Q4 2016 $7,929,000 $417,000 -$996,000 -172% 01 Oct 2016 31 Dec 2016 10-K 27 Feb 2019 2018 FY
Q3 2016 $8,925,000 $7,353,000 +$6,185,000 +530% 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017 2017 Q3
Q2 2016 $2,740,000 $545,000 -$298,000 -35% 01 Apr 2016 30 Jun 2016 10-Q 20 Jul 2016 2016 Q2
Q1 2016 $3,038,000 $448,000 -$1,262,000 -74% 01 Jan 2016 31 Mar 2016 10-Q 10 May 2016 2016 Q1
Q4 2015 $4,300,000 $579,000 -$1,187,000 -67% 01 Oct 2015 31 Dec 2015 10-K 15 Mar 2016 2015 FY
Q3 2015 $5,487,000 $1,168,000 -$398,000 -25% 01 Jul 2015 30 Sep 2015 10-Q 05 Nov 2015 2015 Q3
Q2 2015 $5,885,000 $843,000 -$670,000 -44% 01 Apr 2015 30 Jun 2015 10-Q 20 Jul 2016 2016 Q2
Q1 2015 $6,555,000 $1,710,000 -$876,000 -34% 01 Jan 2015 31 Mar 2015 10-Q 10 May 2016 2016 Q1
Q4 2014 $7,431,000 $1,766,000 +$226,000 +15% 01 Oct 2014 31 Dec 2014 10-K 15 Mar 2016 2015 FY
Q3 2014 $7,205,000 $1,566,000 -$117,000 -7% 01 Jul 2014 30 Sep 2014 10-Q 05 Nov 2015 2015 Q3
Q2 2014 $7,322,000 $1,513,000 -$78,000 -4.9% 01 Apr 2014 30 Jun 2014 10-Q 06 Aug 2015 2015 Q2
Q1 2014 $7,400,000 $2,586,000 +$1,370,000 +113% 01 Jan 2014 31 Mar 2014 10-Q 07 May 2015 2015 Q1
Q4 2013 $6,030,000 $1,540,000 +$577,000 +60% 01 Oct 2013 31 Dec 2013 10-K 15 Mar 2016 2015 FY
Q3 2013 $5,453,000 $1,683,000 +$882,000 +110% 01 Jul 2013 30 Sep 2013 10-Q 06 Nov 2014 2014 Q3
Q2 2013 $4,571,000 $1,591,000 +$860,000 +118% 01 Apr 2013 30 Jun 2013 10-Q 06 Aug 2014 2014 Q2
Q1 2013 $3,711,000 $1,216,000 +$389,000 +47% 01 Jan 2013 31 Mar 2013 10-Q 08 May 2014 2014 Q1
Q4 2012 $3,322,000 $963,000 01 Oct 2012 31 Dec 2012 10-K 12 Mar 2015 2014 FY
Q3 2012 $801,000 -$66,000 -7.6% 01 Jul 2012 30 Sep 2012 10-Q 04 Nov 2013 2013 Q3
Q2 2012 $731,000 -$81,000 -10% 01 Apr 2012 30 Jun 2012 10-Q 01 Aug 2013 2013 Q2
Q1 2012 $827,000 01 Jan 2012 31 Mar 2012 10-Q 30 Apr 2013 2013 Q1
Q3 2011 $867,000 01 Jul 2011 30 Sep 2011 10-Q 06 Nov 2012 2012 Q3
Q2 2011 $812,000 01 Apr 2011 30 Jun 2011 10-Q 02 Aug 2012 2012 Q2

MADRIGAL PHARMACEUTICALS, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $79,880,000 +$30,145,000 +61% 01 Jan 2024 31 Dec 2024 10-K 26 Feb 2025 2024 FY
2023 $49,735,000 +$18,110,000 +57% 01 Jan 2023 31 Dec 2023 10-K 26 Feb 2025 2024 FY
2022 $31,625,000 +$4,752,000 +18% 01 Jan 2022 31 Dec 2022 10-K 26 Feb 2025 2024 FY
2021 $26,873,000 +$6,143,000 +30% 01 Jan 2021 31 Dec 2021 10-K 28 Feb 2024 2023 FY
2020 $20,730,000 -$2,029,000 -8.9% 01 Jan 2020 31 Dec 2020 10-K/A 03 Mar 2023 2022 FY
2019 $22,759,000 +$9,270,000 +69% 01 Jan 2019 31 Dec 2019 10-K 24 Feb 2022 2021 FY
2018 $13,489,000 +$10,235,000 +315% 01 Jan 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
2017 $3,254,000 -$4,675,000 -59% 01 Jan 2017 31 Dec 2017 10-K 26 Feb 2020 2019 FY
2016 $7,929,000 +$3,629,000 +84% 01 Jan 2016 31 Dec 2016 10-K 27 Feb 2019 2018 FY
2015 $4,300,000 -$3,131,000 -42% 01 Jan 2015 31 Dec 2015 10-K 15 Mar 2016 2015 FY
2014 $7,431,000 +$1,401,000 +23% 01 Jan 2014 31 Dec 2014 10-K 15 Mar 2016 2015 FY
2013 $6,030,000 +$2,708,000 +82% 01 Jan 2013 31 Dec 2013 10-K 15 Mar 2016 2015 FY
2012 $3,322,000 -$32,000 -0.95% 01 Jan 2012 31 Dec 2012 10-K 12 Mar 2015 2014 FY
2011 $3,354,000 -$694,000 -17% 01 Jan 2011 31 Dec 2011 10-K 11 Mar 2014 2013 FY
2010 $4,048,000 01 Jan 2010 31 Dec 2010 10-K 14 Mar 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.